ArticleThe Journal of pharmacology and experimental therapeutics2024
Select Minor Cannabinoids from
Article in The Journal of pharmacology and experimental therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Side-Chain Homologs of ΔMolecular neurobiology · 2026Article
- Neuropharmacology of Cannabinoids: A Comprehensive Review of Preclinical and Clinical Evidence for Hemp-Derived Extracts and Active Compounds.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Minor cannabinoids CBD, CBG, CBN, and CBC differentially modulate sensory neuron activation.The Journal of pharmacology and experimental therapeutics · 2026Article
- Barettin, a Nonopioid, Nonhallucinogenic Marine Natural Product with Antihyperalgesic Properties Mediated by 5HT2A Inverse Agonism.Journal of natural products · 2026Article
- Anti-inflammatory and analgesic potential of minor cannabinoids in vivo.Journal of cannabis research · 2026Article
- Cannabidiol/cannabigerol exposure and neuropathy-related outcomes after neurotoxic chemotherapy: a real-world cohort study.Frontiers in pain research (Lausanne, Switzerland) · 2026Article
- Derivation of a health-based guidance value for ΔEFSA journal. European Food Safety Authority · 2025Article
- Minor Cannabinoids CBD, CBG, CBN and CBC differentially modulate sensory neuron activation.bioRxiv : the preprint server for biology · 2025Article
- Select terpenes from Cannabis sativa are antinociceptive in mouse models of post-operative pain and fibromyalgia via adenosine APharmacological reports : PR · 2025Article
- Nav1.8, an analgesic target for nonpsychotomimetic phytocannabinoids.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Modulatory Effects of "Minor" Cannabinoids in an in vitro Model of Neuronal Hypersensitivity.Journal of pain research · 2025Article
- Pharmacokinetics and pharmacodynamics of cannabigerol (CBG) in the C57BL/6Crl mouse.Frontiers in pharmacology · 2025Article
- Elucidation on the In Vivo Activity of the Bivalent Opioid Peptide MACE2 against Several Types of Chronic Pain.ACS omega · 2024Article
- Minor Cannabinoids as an Emerging Frontier for Pain Relief.The Journal of pharmacology and experimental therapeutics · 2024Article
- Chemotherapy-Induced Peripheral Neuropathy: A Recent Update on Pathophysiology and Treatment.Life (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Chronic pain conditions affect nearly 20% of the population in the United States. Current medical interventions, such as opioid drugs, are effective at relieving pain but are accompanied by many undesirable side effects. This is one reason increased numbers of chronic pain patients have been turning to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.